Timeline

Dated events in the published records, newest first: regulatory decisions, guideline recommendations and editions, study dates from their registries and milestones that happened. Each date is shown as precisely as its record states it.

267 events. A year or a month is never shown as a day, and a year-only date sorts below the dated events of that year. 19 are registry dates that the registry does not mark as reached, so each says so. Expected future events are on the calendar. (page 2 of 3)

10,177 registry records are not listed here: a program assembled them, and a registry changes them without notice. A registry trial shows its own dates on its page. Expected registry dates are on the calendar.

2021 33

  1. Supplemental approval Dapagliflozin (Farxiga)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202293 · Where: United States

    Source: openFDA Drugs@FDA record for NDA202293: FARXIGA (dapagliflozin tablets)

  2. Recommended Ambulatory blood pressure monitoring (ABPM)

    Issued by: U.S. Preventive Services Task Force · Where: United States · Strength: Part of a recommendation graded A. The grade covers the statement to screen with an office reading and confirm with measurements outside the clinic, not this method alone.

    Source: Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement

  3. Recommended Home blood pressure monitoring

    Issued by: U.S. Preventive Services Task Force · Where: United States · Strength: Part of a recommendation graded A. The grade covers the statement to screen with an office reading and confirm with measurements outside the clinic, not this method alone.

    Source: Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement

  4. Supplemental approval Evolocumab (Repatha)

    Authority: U.S. Food and Drug Administration · Pathway: BLA · Submission: BLA125522 · Where: United States

    Source: Drugs@FDA application BLA125522: REPATHA (evolocumab) (openFDA drugsfda record)

  5. Supplemental approval Sacubitril/valsartan (Entresto)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA207620 · Where: United States

    Source: openFDA Drugs@FDA record for NDA207620: ENTRESTO (sacubitril and valsartan tablets)

2020 21

  1. Supplemental approval Dapagliflozin (Farxiga)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202293 · Where: United States

    Source: openFDA Drugs@FDA record for NDA202293: FARXIGA (dapagliflozin tablets)

  2. Supplemental approval Rivaroxaban (Xarelto)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202439 · Where: United States

    Source: FDA drug application NDA202439 (openFDA Drugs@FDA record)

  3. Supplemental approval Semaglutide injection for diabetes (Ozempic)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA209637 · Where: United States

    Source: FDA New Drug Application NDA209637: Ozempic (openFDA drugsfda record)

2019 20

  1. Supplemental approval Dapagliflozin (Farxiga)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202293 · Where: United States

    Source: openFDA Drugs@FDA record for NDA202293: FARXIGA (dapagliflozin tablets)

  2. Supplemental approval Sacubitril/valsartan (Entresto)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA207620 · Where: United States

    Source: openFDA Drugs@FDA record for NDA207620: ENTRESTO (sacubitril and valsartan tablets)

  3. Supplemental approval Dapagliflozin (Farxiga)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202293 · Where: United States

    Source: openFDA Drugs@FDA record for NDA202293: FARXIGA (dapagliflozin tablets)

2018 11

  1. Supplemental approval Rivaroxaban (Xarelto)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202439 · Where: United States

    Source: FDA drug application NDA202439 (openFDA Drugs@FDA record)

2017 14

  1. Supplemental approval Evolocumab (Repatha)

    Authority: U.S. Food and Drug Administration · Pathway: BLA · Submission: BLA125522 · Where: United States

    Source: Drugs@FDA application BLA125522: REPATHA (evolocumab) (openFDA drugsfda record)

  2. Supplemental approval Evolocumab (Repatha)

    Authority: U.S. Food and Drug Administration · Pathway: BLA · Submission: BLA125522 · Where: United States

    Source: Drugs@FDA application BLA125522: REPATHA (evolocumab) (openFDA drugsfda record)

  3. Supplemental approval Dapagliflozin (Farxiga)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202293 · Where: United States

    Source: openFDA Drugs@FDA record for NDA202293: FARXIGA (dapagliflozin tablets)

2016 13

  1. Supplemental approval Empagliflozin (Jardiance)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA204629 · Where: United States

    Source: openFDA Drugs@FDA record for NDA204629: JARDIANCE (empagliflozin tablets)

  2. Supplemental approval Evolocumab (Repatha)

    Authority: U.S. Food and Drug Administration · Pathway: BLA · Submission: BLA125522 · Where: United States

    Source: Drugs@FDA application BLA125522: REPATHA (evolocumab) (openFDA drugsfda record)

  3. Study start SECURE Registry does not say if reached

    Source: Secondary Prevention of Cardiovascular Disease in the Elderly Trial

  4. Supplemental approval Rivaroxaban (Xarelto)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202439 · Where: United States

    Source: FDA drug application NDA202439 (openFDA Drugs@FDA record)

  5. Supplemental approval Empagliflozin (Jardiance)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA204629 · Where: United States

    Source: openFDA Drugs@FDA record for NDA204629: JARDIANCE (empagliflozin tablets)

2015 19

  1. Supplemental approval Dabigatran (Pradaxa)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA022512 · Where: United States

    Source: FDA drug application NDA022512 (openFDA Drugs@FDA record)

  2. Supplemental approval Empagliflozin (Jardiance)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA204629 · Where: United States

    Source: openFDA Drugs@FDA record for NDA204629: JARDIANCE (empagliflozin tablets)